tradingkey.logo
tradingkey.logo
Suchen

ImmuCell Corp

ICCC
Zur Watchlist hinzufügen
10.290USD
-0.710-6.45%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
93.09MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über ImmuCell Corp Unternehmen

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

ImmuCell Corp Informationen

BörsenkürzelICCC
Name des UnternehmensImmuCell Corp
IPO-datumMay 01, 1987
CEOte Boekhorst (Olivier)
Anzahl der mitarbeiter69
WertpapierartOrdinary Share
GeschäftsjahresendeMay 01
Addresse56 Evergreen Drive
StadtPORTLAND
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl04103
Telefon12078782770
Websitehttps://immucell.com/
BörsenkürzelICCC
IPO-datumMay 01, 1987
CEOte Boekhorst (Olivier)

Führungskräfte von ImmuCell Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von ImmuCell Corp?

Die fünf größten Anteilseigner von ImmuCell Corp sind: Mr. Michael F. Brigham

Wie viele Institutionen halten Anteile an ImmuCell Corp (ICCC)?

Mit Stand vom 2026Q1 halten 48 Institutionen Anteile an ImmuCell Corp, mit einem Gesamtmarktwert von etwa 2.16M, was 23.86% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 228934.00 gestiegen.

Was ist die größte Einnahmequelle von ImmuCell Corp?

Am 2026Q1 erzielte das Geschäft mit First Defense® product line für ImmuCell Corp den höchsten Umsatz in Höhe von 27.45M, was 99.29% des Gesamtumsatzes entspricht.